{"id":67348,"date":"2026-06-04T21:21:35","date_gmt":"2026-06-04T13:21:35","guid":{"rendered":"https:\/\/flcube.com\/?p=67348"},"modified":"2026-06-04T21:21:36","modified_gmt":"2026-06-04T13:21:36","slug":"lundbeck-partners-with-cradle-to-deploy-ai-guided-protein-engineering-for-cns-antibody-discovery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67348","title":{"rendered":"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>H. Lundbeck A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/HLUBF:OTCMKTS\">OTCMKTS: HLUBF<\/a>) announced on <strong>June 3, 2026<\/strong>, a strategic partnership with <strong>Cradle<\/strong>, an AI-driven protein engineering company, to establish <strong>Lundbeck&#8217;s first end-to-end AI-guided protein engineering workflow<\/strong> for discovering and optimizing <strong>biotherapeutics targeting central nervous system (CNS) diseases<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-partnership-framework-amp-technological-integration\" class=\"wp-block-heading\">Partnership Framework &amp; Technological Integration<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Lundbeck (OTCMKTS: HLUBF) + Cradle (AI protein engineering platform)<\/td><\/tr><tr><td><strong>Primary Focus<\/strong><\/td><td>CNS disease antibody programs (two initial targets)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Cradle&#8217;s generative AI for protein design<\/td><\/tr><tr><td><strong>Workflow Innovation<\/strong><\/td><td>End-to-end AI-guided protein engineering with continuous feedback loops<\/td><\/tr><tr><td><strong>Implementation Team<\/strong><\/td><td>Lundbeck protein engineers + computational biologists<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration represents Lundbeck&#8217;s strategic entry into AI-powered biotherapeutic discovery, marking a significant evolution from traditional protein engineering approaches.<\/p>\n\n\n\n<h2 id=\"h-ai-driven-workflow-architecture\" class=\"wp-block-heading\">AI-Driven Workflow Architecture<\/h2>\n\n\n\n<h3 id=\"h-continuous-learning-system\" class=\"wp-block-heading\">Continuous Learning System<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Feedback Mechanism:<\/strong> Experimental results continuously fed back into AI model<\/li>\n\n\n\n<li><strong>Iterative Improvement:<\/strong> Each cycle enhances prediction accuracy for subsequent designs<\/li>\n\n\n\n<li><strong>Accelerated Convergence:<\/strong> Reduces time required to identify viable lead candidates<\/li>\n\n\n\n<li><strong>Data Integration:<\/strong> Combines wet-lab experimental data with computational predictions<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-efficiency-gains\" class=\"wp-block-heading\">Efficiency Gains<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced Wet-Lab Iterations:<\/strong> Minimizes costly and time-consuming laboratory experiments<\/li>\n\n\n\n<li><strong>Higher-Quality Candidates:<\/strong> AI optimization produces superior antibody properties<\/li>\n\n\n\n<li><strong>Resource Optimization:<\/strong> Focuses experimental resources on highest-potential candidates<\/li>\n\n\n\n<li><strong>Speed-to-Clinic:<\/strong> Accelerates timeline from target identification to lead candidate selection<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-therapeutic-focus-amp-strategic-rationale\" class=\"wp-block-heading\">Therapeutic Focus &amp; Strategic Rationale<\/h2>\n\n\n\n<h3 id=\"h-cns-disease-targeting\" class=\"wp-block-heading\">CNS Disease Targeting<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Initial Programs:<\/strong> Two undisclosed antibody programs for central nervous system disorders<\/li>\n\n\n\n<li><strong>Therapeutic Challenge:<\/strong> CNS antibodies require exceptional specificity and blood-brain barrier penetration<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Limited effective biotherapeutic options for many neurological conditions<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> High-value indications with significant patient populations<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-lundbeck-s-strategic-evolution\" class=\"wp-block-heading\">Lundbeck&#8217;s Strategic Evolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Beyond Small Molecules:<\/strong> Expands beyond traditional small molecule CNS portfolio<\/li>\n\n\n\n<li><strong>Biotherapeutics Investment:<\/strong> Demonstrates commitment to next-generation CNS therapies<\/li>\n\n\n\n<li><strong>Technology Leadership:<\/strong> Positions Lundbeck at forefront of AI-driven drug discovery<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Addresses growing competition in CNS space through innovation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-cradle-platform-capabilities\" class=\"wp-block-heading\">Cradle Platform Capabilities<\/h2>\n\n\n\n<h3 id=\"h-generative-ai-technology\" class=\"wp-block-heading\">Generative AI Technology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Protein Design:<\/strong> AI models trained on vast protein structure and function datasets<\/li>\n\n\n\n<li><strong>Property Optimization:<\/strong> Simultaneous optimization of multiple antibody characteristics<\/li>\n\n\n\n<li><strong>Novel Sequence Generation:<\/strong> Creates previously unexplored protein sequences with desired properties<\/li>\n\n\n\n<li><strong>Stability Prediction:<\/strong> Accurately forecasts developability and manufacturability attributes<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-scientific-validation\" class=\"wp-block-heading\">Scientific Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Proven Track Record:<\/strong> Multiple successful protein engineering campaigns across therapeutic areas<\/li>\n\n\n\n<li><strong>Industry Adoption:<\/strong> Growing adoption by major pharmaceutical companies<\/li>\n\n\n\n<li><strong>Technical Integration:<\/strong> Seamless workflow integration with existing laboratory infrastructure<\/li>\n\n\n\n<li><strong>Scalability:<\/strong> Platform adaptable to diverse protein engineering challenges<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-amp-market-context\" class=\"wp-block-heading\">Strategic Implications &amp; Market Context<\/h2>\n\n\n\n<h3 id=\"h-for-lundbeck\" class=\"wp-block-heading\">For Lundbeck<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> Adds biotherapeutic modality to predominantly small molecule portfolio<\/li>\n\n\n\n<li><strong>Innovation Credibility:<\/strong> Demonstrates commitment to cutting-edge drug discovery technologies<\/li>\n\n\n\n<li><strong>Resource Efficiency:<\/strong> Reduces development costs through AI-guided experimental design<\/li>\n\n\n\n<li><strong>Timeline Acceleration:<\/strong> Potentially shortens preclinical development by 30-50%<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-cradle\" class=\"wp-block-heading\">For Cradle<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Validation:<\/strong> Partnership with established CNS leader validates platform capabilities<\/li>\n\n\n\n<li><strong>Therapeutic Expansion:<\/strong> Extends platform application to challenging CNS antibody space<\/li>\n\n\n\n<li><strong>Commercial Momentum:<\/strong> Builds on growing portfolio of pharmaceutical partnerships<\/li>\n\n\n\n<li><strong>Technical Showcase:<\/strong> Demonstrates platform effectiveness in complex biotherapeutic discovery<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-cns-biotherapeutics-market\" class=\"wp-block-heading\">CNS Biotherapeutics Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High Barrier to Entry:<\/strong> CNS antibody development historically challenging due to delivery and safety constraints<\/li>\n\n\n\n<li><strong>Premium Valuation:<\/strong> Successful CNS biotherapeutics command significant market premiums<\/li>\n\n\n\n<li><strong>Unmet Medical Need:<\/strong> Large patient populations with limited treatment options<\/li>\n\n\n\n<li><strong>Regulatory Pathways:<\/strong> Established frameworks for CNS biotherapeutic approval<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-innovation-context\" class=\"wp-block-heading\">Competitive Landscape &amp; Innovation Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The partnership reflects the broader industry trend toward AI-augmented drug discovery, particularly in complex therapeutic areas like CNS where traditional approaches have yielded limited success. By combining Lundbeck&#8217;s deep CNS expertise with Cradle&#8217;s generative AI capabilities, the collaboration addresses one of biopharmaceutical development&#8217;s most persistent challenges: efficiently designing proteins with multiple optimized properties for difficult-to-treat neurological conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership outcomes, development timelines, and technological capabilities. Actual results may differ materially due to scientific challenges, AI model performance, experimental validation outcomes, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>H. Lundbeck A\/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,4774,1581,2804],"class_list":["post-67348","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-cradle","tag-h-lundbeck","tag-otcmkts-hlubf"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"H. Lundbeck A\/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle, an AI-driven protein engineering company, to establish Lundbeck&#039;s first end-to-end AI-guided protein engineering workflow for discovering and optimizing biotherapeutics targeting central nervous system (CNS) diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67348\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery\" \/>\n<meta property=\"og:description\" content=\"H. Lundbeck A\/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle, an AI-driven protein engineering company, to establish Lundbeck&#039;s first end-to-end AI-guided protein engineering workflow for discovering and optimizing biotherapeutics targeting central nervous system (CNS) diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67348\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T13:21:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T13:21:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67348#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67348\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery\",\"datePublished\":\"2026-06-04T13:21:35+00:00\",\"dateModified\":\"2026-06-04T13:21:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67348\"},\"wordCount\":610,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"Cradle\",\"H. Lundbeck\",\"OTCMKTS: HLUBF\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67348#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67348\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67348\",\"name\":\"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-04T13:21:35+00:00\",\"dateModified\":\"2026-06-04T13:21:36+00:00\",\"description\":\"H. Lundbeck A\\\/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle, an AI-driven protein engineering company, to establish Lundbeck's first end-to-end AI-guided protein engineering workflow for discovering and optimizing biotherapeutics targeting central nervous system (CNS) diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67348#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67348\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67348#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery - Insight, China&#039;s Pharmaceutical Industry","description":"H. Lundbeck A\/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle, an AI-driven protein engineering company, to establish Lundbeck's first end-to-end AI-guided protein engineering workflow for discovering and optimizing biotherapeutics targeting central nervous system (CNS) diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67348","og_locale":"en_US","og_type":"article","og_title":"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery","og_description":"H. Lundbeck A\/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle, an AI-driven protein engineering company, to establish Lundbeck's first end-to-end AI-guided protein engineering workflow for discovering and optimizing biotherapeutics targeting central nervous system (CNS) diseases.","og_url":"https:\/\/flcube.com\/?p=67348","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-04T13:21:35+00:00","article_modified_time":"2026-06-04T13:21:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67348#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67348"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery","datePublished":"2026-06-04T13:21:35+00:00","dateModified":"2026-06-04T13:21:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67348"},"wordCount":610,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","Cradle","H. Lundbeck","OTCMKTS: HLUBF"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67348#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67348","url":"https:\/\/flcube.com\/?p=67348","name":"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-04T13:21:35+00:00","dateModified":"2026-06-04T13:21:36+00:00","description":"H. Lundbeck A\/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle, an AI-driven protein engineering company, to establish Lundbeck's first end-to-end AI-guided protein engineering workflow for discovering and optimizing biotherapeutics targeting central nervous system (CNS) diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67348#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67348"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67348#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67348"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67348\/revisions"}],"predecessor-version":[{"id":67350,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67348\/revisions\/67350"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}